Gestational Trophoblastic Neoplasia, Version 2.2019

Nadeem R. Abu-Rustum, MD^{1,*}; Catheryn M. Yashar, MD²; Sarah Bean, MD³; Kristin Bradley, MD⁴; Susana M. Campos, MD, MPH, MS⁵; Hye Sook Chon, MD⁶; Christina Chu, MD⁷; David Cohn, MD⁸; Marta Ann Crispens, MD⁹; Shari Damast, MD¹⁰; Oliver Dorigo, MD, PhD¹¹; Patricia J. Eifel, MD¹²; Christine M. Fisher, MD, MPH¹³; Peter Frederick, MD¹⁴; David K. Gaffney, MD, PhD¹⁵; Ernest Han, MD, PhD¹⁶; Warner K. Huh, MD¹⁷; John R. Lurain, III, MD^{18,*}; Andrea Mariani, MD¹⁹; David Mutch, MD^{20,*}; Christa Nagel, MD²¹; Larissa Nekhlyudov, MD, MPH⁵; Amanda Nickles Fader, MD²²; Steven W. Remmenga, MD²³; R. Kevin Reynolds, MD^{24,*}; Rachel Sisodia, MD²⁵; Todd Tillmanns, MD²⁶; Stefanie Ueda, MD²⁷; Emily Wyse²⁸; Nicole R. McMillan, MS, CHES²⁹; and Jillian Scavone, PhD²⁹

ABSTRACT

Gestational trophoblastic neoplasia (GTN), a subset of gestational trophoblastic disease (GTD), occurs when tumors develop in the cells that would normally form the placenta during pregnancy. The NCCN Guidelines for Gestational Trophoblastic Neoplasia provides treatment recommendations for various types of GTD including hydatidiform mole, persistent post-molar GTN, low-risk GTN, high-risk GTN, and intermediate trophoblastic tumor.

J Natl Compr Canc Netw 2019;17(11):1374–1391
doi: 10.6004/jnccn.2019.0053

¹Memorial Sloan Kettering Cancer Center; ²UC San Diego Moores Cancer Center; ³Duke Cancer Institute; ⁴University of Wisconsin Carbone Cancer Center; ⁵Dana-Farber/Brigham and Women's Cancer Center; ⁶Moffitt Cancer Center; ⁷Fox Chase Cancer Center; ⁸The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; ⁹Vanderbilt-Ingram Cancer Center; ¹⁰Yale Cancer Center/Smilow Cancer Hospital; ¹¹Stanford Cancer Institute; ¹²The University of Texas MD Anderson Cancer Center; ¹³University of Colorado Cancer Center; ¹⁴Roswell Park Comprehensive Cancer Center; ¹⁵Huntsman Cancer Institute at the University of Utah; ¹⁶City of Hope National Medical Center; ¹⁷O'Neal Comprehensive Cancer Center at UAB; ¹⁸Robert H. Lurie Comprehensive Cancer Center of Northwestern University; ¹⁹Mayo Clinic Cancer Center; ²⁰Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; ²¹Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; ²²The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; ²³Fred & Pamela Buffett Cancer Center; ²⁴University of Michigan Rogel Cancer Center; ²⁵Massachusetts General Hospital; ²⁶St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; ²⁷UCSF Helen Diller Family Comprehensive Cancer Center; ²⁸Patient Advocate; and ²⁹National Comprehensive Cancer Network

*Discussion Writing Committee Member

NCCN CATEGORIES OF EVIDENCE AND CONSENSUS

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Clinical trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PLEASE NOTE

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network[®] (NCCN[®]) makes no representations or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

© National Comprehensive Cancer Network, Inc. 2019. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Disclosures for the NCCN Gestational Trophoblastic Neoplasia Panel

At the beginning of each NCCN Guidelines Panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

Individual disclosures for the NCCN Gestational Trophoblastic Neoplasia Panel members can be found on page 1391.

(The most recent version of these guidelines and accompanying disclosures are available at NCCN.org.)

The complete and most recent version of these guidelines is available free of charge at NCCN.org.

Hydatidiform Mole (Noninvasive)

^aIf chest x-ray positive for metastases, manage as GTN after initial uterine evacuation.

^bUse largest curette feasible. Sharp curettage after suction. Use uterotonic drugs after initiating evacuation of uterus. Oxytocin receptors may be absent.

^cProphylactic chemotherapy with methotrexate or dactinomycin may be considered at the time of evacuation of a hydatidiform mole in patients at high risk for postmolar gestational trophoblastic neoplasia (age >40 years, hCG >100,000 mIU/mL, excessive uterine enlargement, and theca lutein cysts >6 cm) when hCG follow-up is unavailable or unreliable (Wang Q, Fu J, Hu L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2017 Sep 11;9:CD007289).

^dHysterectomy may be considered as initial treatment for hydatidiform mole in patients who are older or do not wish to preserve fertility.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

HM-1

Overview

Gestational trophoblastic disease (GTD) refers to a group of benign and malignant tumors that develop in the uterus from placental tissue. Pathogenesis of GTD is unique in that maternal tumors arise from gestational tissue that can have locally invasive or metastatic potential. Historical data on incidence of GTD varies widely by region, with higher incidence reported in Asia compared with Europe and North America. These differences are thought to be due at least in part to varying diagnostic criteria, reporting practices, quality of epidemiologic data, and diet and nutrition. In the United States, the reported incidence of GTD is approximately one of every 1,000 pregnancies.^{1–3}

The most common form of GTD is hydatidiform mole (HM), also known as molar pregnancy. HMs are considered benign, premalignant disease. Malignant forms of GTD are collectively referred to as gestational trophoblastic neoplasia (GTN), and include invasive mole, choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). HM encompasses about 80% of all GTD; invasive moles account for 15%; and choriocarcinoma and other rarer

types of GTN comprise the remaining 5%.⁴ Cure rates are approaching 100%, and treatment typically allows for fertility preservation.^{4,5}

Types of GTD

HM occurs as a result of abnormal fertilization and is characterized as complete or partial based on differences in morphology, karyotype, and malignant potential. Most complete moles (80%) occur as a result of abnormal fertilization of an ovum lacking nuclear DNA, and have 2 identical paternal chromosome complements derived from duplication of the haploid genome of a single sperm. The remaining 20% occur as a result of dispermy (fertilization by 2 sperm). Partial moles occur when an ovum retains its nucleus and abnormal fertilization occurs in one of 2 ways: (1) fertilization by a single sperm with subsequent paternal chromosome duplication or (2) via dispermy. Partial HMs can contain fetal tissue, but complete moles do not.

Postmolar GTN, which includes invasive mole and choriocarcinoma, develops in about 15% to 20% of complete moles, but in only 1% to 5% of partial moles.^{2,3,6,7} The reported incidence of GTN after molar pregnancy is 18%

Hydatidiform Mole (Noninvasive)

^eDoppler pelvic ultrasound to confirm absence of pregnancy, measure uterine size, and determine volume and vasculature of tumor within the uterus.

^fIf the chest x-ray is normal, no further imaging is indicated before commencing treatment. If the chest x-ray shows metastases, CT scan of the abdomen/pelvis and MRI of the brain are indicated.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

HM-2

to 29%.^{2,3,8,9} This rate appears to be stable despite the progressively earlier diagnosis of complete HM.⁹ Invasive moles arise from extension of HM into the myometrium via tissue or venous channels. Approximately 15% of invasive moles metastasize to the lung or vagina. Persistent elevated human chorionic gonadotropin (hCG) after evacuation of a molar pregnancy most often leads to the diagnosis of invasive mole.² Choriocarcinoma develops from villous trophoblast. Features of these malignant epithelial tumors include abnormal trophoblastic hyperplasia and anaplasia, hCG production, absence of chorionic villi, hemorrhage, and necrosis.^{2,3} Choriocarcinoma has been reported to occur with different types of pregnancy events, including HM (50%), term or preterm gestation (25%), and tubal pregnancy or abortion (25%). Approximately 2% to 3% of HMs progress to choriocarcinoma.

The intermediate trophoblastic tumors (ITT), including PSTT and ETT, are rare subtypes of GTN with an incidence of about 1 in 100,000 pregnancies, representing approximately 1% of all GTN cases.¹⁰ Most PSTTs follow nonmolar gestations and present months to years after the antecedent pregnancy. Less often, PSTT develops after evacuation of HM.⁴ PSTT arises from interstitial

trophoblast at the placental implantation site and consists predominately of mononuclear intermediate trophoblast without chorionic villi, infiltrating in sheets or cords between myometrial fibers. It is associated with less vascular invasion, necrosis, and hemorrhage than choriocarcinoma.

ETT is a rare variant of PSTT that simulates carcinoma. Based on morphologic and histochemical features, it appears to develop from neoplastic transformation of chorionic-type intermediate trophoblast. ETT typically presents years after term delivery.

Hydatidiform Mole

Presentation and Workup

Patients with HM commonly present with vaginal bleeding, typically around 6 to 16 weeks of gestation. Due to widespread ultrasound screening during early pregnancy and accurate hCG testing, most cases of HM are detected before the onset of additional signs such as uterine enlargement beyond that expected for gestation date, preeclampsia, hyperemesis, anemia, and theca lutein ovarian cysts.²⁻⁴ Partial HMs tend to grow more

^aIf visible lesions are seen in lower genital tract, do NOT biopsy due to risk of hemorrhage.

^bIf contrast is contraindicated, other imaging techniques such as MRI may be considered.

^cIf hCG is elevated with no evidence of disease on imaging, consider possibility of phantom hCG. Consult with laboratory medicine/pathology to test for phantom hCG with serial dilution study or comparison of serum to urine hCG.

^dIf hCG is elevated, but hyperglycosylated hCG is normal, quiescent GTN may be diagnosed and not treated.

^eSee FIGO Staging (ST-1*) and Prognostic Scoring Index for GTN (ST-2*).

^fConsider consultation with a clinician or center with expertise in management of gestational trophoblastic diseases.

^gPrognostic scoring is not valid for intermediate tumors.

*Available online, in these guidelines, at NCCN.org.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

GTN-1

slowly and may present later in the first or early second trimester, often with symptoms of incomplete or missed abortion and diagnosis made on histologic examination of the curettage specimen.^{2,3}

Initial determination of suspected HM is often made based on ultrasound findings in combination with clinical symptoms and hCG levels. Due to hyperplastic trophoblastic cells in complete HM, many patients will have marked elevations in hCG, at times greater than 100,000 IU/L. However, such elevations in hCG are observed in fewer than 10% of patients with partial HM. Characteristic ultrasound findings of complete HM include enlarged uterus with a heterogenous mass (ie, snowstorm appearance). Hydropic/swollen chorionic villi lead to the appearance of small cystic spaces, creating a vesicular pattern. However, these characteristics may not be readily observed with the diagnosis of HM early in the first trimester. As molar pregnancy advances, these cystic spaces become larger and more numerous. Features that may be noted on ultrasound imaging of partial HM include focal cystic spaces within the placenta, gestational sac that is empty or elongated along the transverse axis, and/or fetal anomalies or fetal demise.^{2-4,8,11}

The NCCN Panel recommends workup of patients with HM to include history and physical; pelvic ultrasound;

quantitative hCG assay; complete blood count with platelets; liver, renal, and thyroid function tests; and blood type and screen. Recommended imaging also includes chest X-ray.

Treatment

Initial treatment of HM in women who wish to preserve fertility is suction dilation and curettage, preferably performed under ultrasound guidance to reduce the risk of uterine perforation.^{8,12} Rho(D) immunoglobulin should be administered at the time of evacuation to patients with Rh-negative blood types.⁸ To reduce the risk of heavy bleeding, uterotonic agents (eg, methylergonovine and/or prostaglandins) should be administered during the procedure and continued for several hours postoperatively.^{2,13} For women who are older or do not wish to preserve fertility, hysterectomy can be considered as an alternative.¹⁴ Histopathologic review and possible genetic testing confirm the diagnosis.

Prophylactic chemotherapy at the time of uterine evacuation is controversial and may reduce the incidence of postmolar GTN by 3% to 8%. A Cochrane data-base review (3 randomized controlled trials [RCTs], n=613) did not conclude sufficient evidence for standard administration of prophylactic chemotherapy to prevent

^hRegimens are continued until 2 full cycle(s) past normalization of the hCG.

ⁱHysterectomy and salpingectomy may be considered if there is localized disease in the uterus and where fertility preservation is not desired. Leave ovaries in situ, even in presence of theca lutein cysts.

^jSee Principles of Systemic Therapy (GTN-A) for specific recommendations.

^khCG plateau during treatment can be defined as a <10% decrease in hCG over 2 treatment cycles (4 weeks total).

^lOral contraceptive pills are preferred because they suppress endogenous luteinizing hormone (LH)/follicle-stimulating hormone (FSH), which may interfere with hCG measurement at low levels.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

GTN-2

postmolar GTN; however, evidence was suggestive that prophylactic chemotherapy may reduce the risk of progression to GTN among women with complete HM at high risk for malignant transformation.¹⁵ The NCCN Guidelines state that prophylactic methotrexate or dactinomycin can be considered for patients deemed at high risk for postmolar GTN. Risk factors for postmolar GTN include age >40 years, hCG levels in excess of 100,000 mIU/mL, excessive uterine enlargement, and/or theca lutein cysts larger than 6 cm.^{2,8,15,16}

Follow-up

Follow-up with hCG monitoring is essential after initial treatment of HM to ensure that hCG levels return to normal. The hCG molecules associated with GTD are more heterogeneous and degraded than those associated with normal pregnancy.^{2,17} Therefore, monitoring should be performed with a quantitative assay capable of detecting all forms of hCG, including beta-hCG, core hCG, nicked-free beta, beta core, and hyperglycosylated forms.^{4,18,19} Postmolar GTN develops in about 15% to 20% of complete moles, but in only 1% to 5% of partial moles. Therefore, careful monitoring can facilitate early detection of persistent GTN. Risk of recurrence is low

(<2%) after a single molar pregnancy but increases significantly for women who experience one or more recurrences.^{2,3,6,12,13,20}

Once normalized, recurrent elevation of hCG has been reported in <1% of patients.^{20,21} The occurrence of GTN following hCG normalization is rare after the recommended 6 months of postnormalization hCG monitoring.²² A recent study showed that patients with complete HM who normalized beyond 56 days after uterine evacuation had a 3.8-fold higher risk of developing postmolar GTN.²⁰

The NCCN Panel recommends hCG assay monitoring every 1 to 2 weeks until levels have normalized, defined in the guidelines as 3 consecutive normal assays. After initial normalization, hCG should be measured twice in 3-month intervals to ensure levels remain normal. If hCG levels remain elevated, treat per the postmolar GTN algorithm.

Postmolar GTN

Postmolar GTN is typically diagnosed using hCG surveillance. The NCCN Guidelines use the FIGO staging criteria for postmolar GTN as meeting one of more of the following criteria after treatment of HM, as indicated by hCG monitoring²³:

^fConsider consultation with a clinician or center with expertise in management of gestational trophoblastic diseases.

ⁱHysterectomy and salpingectomy may be considered if there is localized disease in the uterus and where fertility preservation is not desired. Leave ovaries in situ, even in presence of theca lutein cysts.

^jSee Principles of Systemic Therapy (GTN-A) for specific recommendations.

^mhCG level plateaus (<10% change) for 2 treatment cycles (4 weeks total) or hCG level rises (>10% change) for 1 treatment cycle (2 weeks total).

ⁿDo not start a cycle of methotrexate or dactinomycin if the WBC was <3.0 or the ANC was <1.5 or if there was persistent mucositis >grade 1. CBC and chemistries should not be checked during a chemotherapy cycle; they should only be checked at the start of each cycle.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

GTN-3

- hCG levels plateau for 4 consecutive values over ≥ 3 weeks
- hCG levels rise $\geq 10\%$ for 3 values over ≥ 2 weeks
- hCG persistence 6 months or more after molar evacuation

Assessment and staging of the postmolar GTN should include history and physical examination, Doppler pelvic ultrasound, and chest X-ray to assess for metastatic disease. Doppler pelvic ultrasound is used to confirm the absence of pregnancy, measure uterine size, and to delineate the volume and vascularity of the tumor. If chest X-ray reveals no evidence of metastatic disease, no further imaging is recommended before treatment.

Repeat dilation and curettage or hysterectomy can be considered for persistent postmolar GTN.^{24–26} An observational study conducted over 10 years examined 544 women who underwent second uterine evacuation for persistent GTD.²⁶ Following repeat curettage, 68% had no further evidence of disease or chemotherapy requirements. However, chemotherapy requirement was more likely for patients with a histologic confirmation of persistent trophoblastic disease and for urinary hCG levels in excess of 1,500 IU/L at second evacuation.²⁶ Several groups have discussed the

optimal characteristics of candidates for repeat uterine evacuation.^{26–30}

Repeat surgical treatment should be followed by hCG monitoring every 2 weeks until the patient has 3 consecutive normal assays, with monthly hCG monitoring for an additional 6 months. For evidence of metastatic disease, histopathologic diagnosis of choriocarcinoma, or persistent hCG elevation (ie, plateau or rise), follow recommendations for staging and treatment in the algorithms for GTN.

Gestational Trophoblastic Neoplasia

Presentation and Workup

The presentation of GTN can vary depending on the antecedent pregnancy event and disease type and extent. Postmolar GTN, including invasive mole or choriocarcinoma, can be associated with irregular bleeding after initial treatment of molar pregnancy, an enlarged and irregular uterus, and bilateral ovarian enlargement. However, these signs may be absent in patients with choriocarcinoma associated with normal, nonmolar pregnancies. Trophoblastic tumors have fragile vessels and as a result, metastatic lesions are often hemorrhagic. In addition to bleeding, metastatic lesions may

^eSee FIGO Staging (ST-1*) and Prognostic Scoring Index for GTN (ST-2*).

^fConsider consultation with a clinician or center with expertise in management of gestational trophoblastic diseases.

^gSee Principles of Systemic Therapy (GTN-A) for specific recommendations.

^hIncrease the methotrexate infusion dose in the EMA/CO protocol to 1000 mg/m² and give folinic acid 30 mg every 12 hours for 3 days starting 32 hours after the infusion begins.

^pAlso see Additional Agents Shown to Have Some Activity in Treating Resistant High-Risk GTN (GTN-A).

^qConsider surgery, especially hysterectomy and pulmonary resection, for chemotherapy-resistant disease.

*Available online, in these guidelines, at NCCN.org.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

GTN-4

be associated with neurologic or pulmonary symptoms. ETT and PSTT typically present with irregular uterine bleeding arising after some time has passed from a previous pregnancy.^{2,3,31}

Workup for GTN includes history and physical examination and metastatic imaging workup, to include chest/abdominal/pelvic CT scan with contrast (or MRI if contrast is contraindicated) and brain MRI (preferred) or brain CT if pulmonary metastasis. Visible lesions in the lower genital tract should not be biopsied due to hemorrhage risk. Additionally, the NCCN Panel recommends repeat complete blood count differential with platelets; liver, renal, and thyroid function testing; and hCG assay. If hCG is elevated with no evidence of disease on imaging, consider the possibility of phantom hCG.³² Elevated hCG with normal hyperglycosylated hCG may indicate quiescent GTN not requiring immediate or further treatment.³³

Based on these findings, the GTN should be staged and scored according to the current FIGO staging and prognostic scoring system.^{23,34} GTN staging is based on tumor location and extent: stage I disease is uterine-confined, stage II involves direct extension or metastasis to other genital structures, stage III disease is determined by lung metastasis, and stage IV disease includes

nonpulmonary distant metastasis. The current FIGO prognostic scoring system was adapted from the WHO classification, which incorporated prognostic factors from Bagshawe's scoring system.^{35,36} FIGO prognostic scoring is based on individual risk factors that have been shown to be predictive of GTN that is resistant to single-agent chemotherapy, such as age, antecedent pregnancy, interval from index pregnancy, pretreatment hCG, largest tumor size (including the uterus), site and number of metastases, and previous chemotherapy regimens that were unsuccessful. The sum of individual scores denotes the FIGO prognostic score of low-risk GTN (<7) or high-risk GTN (≥7).^{23,34,37} This prognostic scoring system is not valid for the ITTs, ETT and PSTT.¹⁰

Low-Risk GTN

First-Line Therapy

Low-risk GTN encompasses cases with a FIGO prognostic score ≤6. Standard front-line treatment of low-risk GTN is single-agent chemotherapy using methotrexate or dactinomycin. Numerous studies have evaluated these agents, but differences in inclusion criteria and dosage regimens have made it challenging to determine a superior regimen. Although some experts consider

^fConsider consultation with a clinician or center with expertise in management of gestational trophoblastic diseases.

^jSee Principles of Systemic Therapy (GTN-A) for specific recommendations.

^pAlso see Additional Agents Shown to Have Some Activity In Treating Resistant High-Risk GTN (See GTN-A).

^rReported poor prognostic factors in PSTT are high mitotic rates (>5/10 HPFs), deep myometrial invasion, extensive coagulative necrosis, lymphovascular space invasion (LVSI), and interval since last pregnancy >2 years. (Baergen RN, Rutgers JL, Young RH, et al. Placental site trophoblastic tumors: a study of 55 cases and review of the literature emphasizing factors of prognostic significance. *Gynecol Oncol* 2006;100:511-520).

^sThe incidence of pelvic lymph node metastasis in PSTT/ETT is estimated to be between 5% and 15% in clinical stage I tumors. Therefore, pelvic lymph node biopsy should be considered at the time of hysterectomy, especially with large, deeply invasive tumors.

^tConsider PET/CT for follow-up at the completion of chemotherapy and then every 6–12 months for 2–3 years.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

GTN-5

methotrexate to have a more favorable adverse effect profile, dactinomycin may achieve similar or better efficacy with a less-frequent infusion schedule.^{4,18,37–39} A 2016 Cochrane Database review of RCTs in low-risk GTN showed with moderate-certainty evidence that first-line methotrexate may be more likely to fail than dactinomycin (risk ratio [RR], 3.55; 95% CI, 1.81–6.95; 6 trials, 577 participants; I(2)=61%).³⁹ Similarly, the authors concluded that dactinomycin is more likely to lead to a primary cure than methotrexate (RR, 0.65; 95% CI, 0.57–0.75; 6 trials, 577 participants; I(2)=26%).³⁹ However, 55% of the data came from trials of weekly intramuscular methotrexate, which seems to be less effective than the 5- or 8-day methotrexate regimens. A now closed for lack of accrual phase III RCT (ClinicalTrials.gov identifier: NCT01535053) comparing pulse dactinomycin to multiday methotrexate regimens noted primary remission rates of 75% for pulse dactinomycin versus 88.5% for the multiday methotrexate regimens (5-day > 8-day). Overall quality-of-life scores were similar. Alopecia was more common with dactinomycin; mucositis was more common with the methotrexate regimens; and no patient required multiagent chemotherapy or salvage surgery to reach remission.⁴⁰

Currently supported regimens of dactinomycin include a 5-day regimen (10–12 mcg/kg or flat 0.5 mg dose intravenously, repeated every 2 weeks) or a dactinomycin pulse regimen (1.25 mg/m², intravenously, repeated every 2 weeks).¹⁸ Primary remission rates for initial treatment with 5-day dactinomycin range from 77% to 94%, and for pulse dactinomycin, from 69% to 90%.³⁷ For methotrexate, currently supported regimens include 5-day methotrexate (0.4 mg/kg intravenous or intramuscular daily × 5 days, repeated every 2 weeks) or an 8-day regimen of methotrexate alternating with leucovorin rescue (1.0–1.5 mg/kg intramuscular, every other day × 4 days, alternating with leucovorin, 15 mg by mouth, repeated every 2 weeks).¹⁸ Primary remission rates for multiday methotrexate regimens range from 87% to 93% for the 5-day protocol, and from 74% to 93% for 8-day methotrexate with leucovorin rescue.³⁷

Methotrexate regimens that are no longer recommended due to lesser efficacy include weekly intramuscular methotrexate (30–50 mg/m²) and pulse-dose intravenous infusion methotrexate.^{37,41,42} Although weekly intramuscular methotrexate was successful in 70% of patients with a prognostic score of 0 to 1, the success rate fell to 40% and 12% with a prognostic score of 2 to 4 and 5 to 6, respectively.^{4,41} In a large case series (n=618),

PRINCIPLES OF SYSTEMIC THERAPY

Regimens for Low-Risk GTN

Regimens	Comments/Considerations
Methotrexate 0.4 mg/kg/day IV or IM (max 25 mg/day) daily x 5 days; Repeat every 14 days (category 1) OR 1 mg/kg IM every other day x 4 days (days 1, 3, 5, and 7) Alternating every other day with leucovorin 15 mg PO, 30 hours after each methotrexate dose on days 2, 4, 6, and 8; Repeat every 14 days (category 1)	• A multiday methotrexate regimen is typically used as first-line therapy for low-risk GTN. Due to its toxicity profile, dactinomycin has most often been used as secondary therapy for patients with methotrexate toxicity or effusions contradicting the use of methotrexate. NOT RECOMMENDED • Methotrexate 30–50 mg/m ² IM weekly OR Methotrexate infusion (eg, 300 mg/m ² over 12 hours/leucovorin) due to lesser efficacy.
Dactinomycin 10–12 mcg/kg (or 0.5 mg flat dose) IV daily x 5 days; Repeat every 14 days (category 1) OR 1.25 mg/m ² (max 2 mg) IV pulse; Repeat every 14 days (category 1)	• Dactinomycin pulse regimen should not be used as secondary therapy for methotrexate-resistant disease nor as primary therapy in patients with choriocarcinoma.

Continued

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
 The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

GTN-A
 1 OF 5

8-day methotrexate was comparatively more successful when analyzed by prognostic score subgrouping.⁴³

The guidelines note that a multiday methotrexate regimen is typically used as first-line therapy in low-risk GTN due to its generally favorable toxicity profile. Dactinomycin is often used as a secondary therapy for patients with methotrexate toxicity or effusions contradicting the use of methotrexate. Alternative single-agent options for treatment of low-risk GTN that are primarily used in Asia include etoposide and fluorouracil.^{37,44,45}

NCCN Panel consensus recommendations for monitoring of chemotherapy response is hCG assay at least every 1 or 2 weeks.³⁸ On hCG normalization, continuation of therapy is recommended for 2 to 3 additional treatment cycles past normalization to minimize the risk of recurrence.^{3,5,18} Surveillance should include monthly hCG for 1 year, along with contraception (oral contraception preferred). Chemotherapy resistance is indicated by a plateau in hCG over 3 consecutive cycles or a rise in hCG over 2 consecutive cycles.^{4,38} Second-line chemotherapy is then indicated.

Second-Line Therapy

Currently, there are no RCT data on second-line therapy for low-risk GTN, but general evidence and consensus

supports a change to the alternative single-agent chemotherapy for patients who have had a good initial response to chemotherapy but experience hCG plateau, or for patients who experience toxicity that limits the dose or frequency of treatment.^{4,18,46} Adjuvant hysterectomy and salpingectomy can be considered for patients with localized disease in the uterus for whom fertility preservation is not desired. The ovaries are left in situ, even in the presence of theca lutein cysts.

Second-line dactinomycin is considered to have an acceptable response rate in patients with low levels of hCG, but multiagent chemotherapy may be favored in the second-line setting for patients whose hCG exceeds a given threshold.^{43,47,48} The hCG threshold for considering dactinomycin versus multiagent regimens has been debated and revised over time.^{3,18,43,48,49}

Dactinomycin has been associated with a complete response rate of approximately 75% in large case series of patients with methotrexate-resistant GTN.^{50,51} A retrospective review of 358 patients with low-risk GTN identified 68 patients who were determined to have resistant disease after a 5-day methotrexate regimen (n=68). The complete response rate to secondary dactinomycin was 75%, and all patients who required third-line multiagent chemotherapy with or without surgery

PRINCIPLES OF SYSTEMIC THERAPY

High-Risk GTN: Primary Therapy Options^a

Regimens	Comments/Considerations
EMA/CO: Etoposide, Methotrexate, Dactinomycin/Cyclophosphamide, Vincristine (Repeat every 2 weeks until hCG normalizes, then continue for an additional 6–8 weeks) <ul style="list-style-type: none"> Etoposide 100 mg/m²/day IV on days 1 and 2 Dactinomycin 0.5 mg IV push on days 1 and 2 Methotrexate 300 mg/m² IV infusion over 12 hours on day 1; may be given as 100 mg/m² IV push immediately followed by 200 mg/m² IV infusion over 12 hours Leucovorin 15 mg PO or IM every 12 hours for 4 doses starting 24 hours after start of methotrexate Cyclophosphamide 600 mg/m² IV on day 8 Vincristine 1 mg/m² (maximum of 2 mg) IV over 5–10 minutes on day 8 	<ul style="list-style-type: none"> Consider low-dose induction chemotherapy with etoposide 100 mg/m² IV and cisplatin 20 mg/m² IV on days 1 and 2 every 7 days for 1–3 courses prior to starting EMA/CO in patients with widely metastatic disease (prognostic score >12) who are at significant risk for pulmonary, intraperitoneal, or intracranial hemorrhage. For secondary prophylaxis of neutropenic fever, or for treatment delay: Filgrastim, 300 mcg SC on days 9–14 of each EMA/CO cycle. For patients with brain metastases, increase the methotrexate infusion dose in the EMA/CO protocol to 1000 mg/m² and give leucovorin 30 mg every 12 hours for 3 days starting 32 hours after the infusion begins.

^aUse G-CSF as primary prophylaxis with etoposide/cisplatin or etoposide/carboplatin-based regimens. See NCCN Guidelines for Myeloid Growth Factors.[†]

[†]To view the most recent version of these guidelines, visit NCCN.org.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

Continued

GTN-A
2 OF 5

experienced permanent remission. Clinicopathologic diagnosis of choriocarcinoma (vs postmolar GTN) was significantly associated with resistance to secondary dactinomycin.⁵⁰ In a recent retrospective review of 877 patients with GTN initially treated with 8-day methotrexate, 103 patients required second-line therapy and were placed on a 5-day dactinomycin protocol.⁵¹ Complete response to second-line dactinomycin was observed among 75.7% (n=78). Among the 25 patients who required third-line treatment of resistant disease or relapse, overall survival was 100%.⁵¹

Multiagent Therapy

For disease that is resistant to single-agent chemotherapy, repeat disease workup for metastasis and transition to combination chemotherapy. The following criteria warrant a switch to a multiagent regimen: poor response to initial therapy, significant elevation in hCG level, development of metastasis, or resistance to sequential single-agent chemotherapy regimens.^{3,5} The most commonly used regimen in this setting is EMA/CO (etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine).^{43,46,52} The use of EMA/CO in this setting is based on its efficacy in managing high-risk GTN.⁵³ Cure rates with EMA/CO approach 100% even in

the presence of relapsed/resistant low-risk GTN.^{3,5,52} For persistent or recurrent disease after EMA/CO combination therapy, treat per the high-risk GTN algorithm with etoposide/platinum-based regimens and surgical resection as feasible.

High-Risk GTN

High-risk GTN is defined as FIGO stages II–III disease with a prognostic score ≥ 7 , or FIGO stage IV disease.^{23,34} High-risk disease is relatively rare among patients with postmolar GTN, estimated at only 6% (39/618) in a large case series.⁴³ High-risk GTN should be treated with multiagent chemotherapy. Adjuvant surgery or radiation therapy may be included. With a multimodal approach, cure rates have reached approximately 90%, including almost all patients with only lung/vaginal metastases and 70% for patients with stage IV disease.⁵ Factors associated with poorer outcomes include liver and brain metastases, particularly if co-occurring. However, the prognosis for these patients has improved over time.^{54–56}

Primary Chemotherapy

EMA/CO, in which EMA and CO are given on alternate weeks, is the most commonly used initial regimen for high-risk disease. Based on existing evidence, this regimen

PRINCIPLES OF SYSTEMIC THERAPY

High-Risk GTN: Primary Therapy Options^a – Continued

For highest-risk patients, consider: EMA/EP or EP/EMA • EMA/EP (or EP/EMA) regimen is considered the most appropriate therapy for patients who have responded to EMA/CO but have plateauing low hCG levels or have developed re-elevation of hCG levels after a complete response to EMA/CO.	
Regimens	Comments/Considerations
EMA/EP: Etoposide, Methotrexate, Dactinomycin/Etoposide, Cisplatin (Repeat every 2 weeks) • Etoposide 100 mg/m ² /day IV on days 1 and 2 • Methotrexate 100 mg/m ² IV push followed by 200 mg/m ² IV infusion over 12 hours on day 1 ▶ Leucovorin 15 mg PO or IM every 12 hours for 4 doses starting 24 hours after start of methotrexate • Dactinomycin 0.5 mg IV push on days 1 and 2 • Etoposide 100 mg/m ² IV on day 8 • Cisplatin 75 mg/m ² IV on day 8 • Filgrastim 300 mcg SC on days 9–14 of each treatment cycle	On rare occasions, reduction of the EMA by omission of day 2 etoposide and dactinomycin doses may be needed to avoid extended intervals between courses caused by myelosuppression, which is usually overcome by the primary use of filgrastim.
EP/EMA: Etoposide, Cisplatin/Etoposide, Methotrexate, Dactinomycin (Repeat every 2 weeks) • Etoposide 150 mg/m ² on day 1 • Cisplatin 75 mg/m ² IV on day 1 • Etoposide 100 mg/m ² IV on day 8 • Methotrexate 300 mg/m ² IV infusion over 12 hours on day 8 ▶ Leucovorin 15 mg PO or IM every 12 hours for 4 doses starting 24 hours after start of methotrexate infusion • Dactinomycin 0.5 mg IV on day 8 • Filgrastim 300 mcg SC on days 3–6 and 10–13 of each treatment cycle	For patients with brain metastases, increase the methotrexate infusion dose in the EP/EMA protocol to 1000 mg/m ² IV infusion over 24 hours and give leucovorin 15 mg every 6 hours for 12 doses starting 32 hours after the start of the methotrexate infusion.

^aUse G-CSF as primary prophylaxis with etoposide/cisplatin or etoposide/carboplatin-based regimens. See NCCN Guidelines for Myeloid Growth Factors.[†]

Continued

[†]To view the most recent version of these guidelines, visit NCCN.org.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

GTN-A
3 OF 5

is thought to provide the best combination of efficacy with acceptable toxicity for treating patients with high-risk GTN. Multiple groups have confirmed the efficacy of EMA/CO, reporting complete response rates of 62% to 78% and long-term survival rates of 85% to 94%.^{52,53,57–64}

Reports of other regimens that have been used in first-line treatment of high-risk GTN include:

- EMA/EP (etoposide, methotrexate, dactinomycin alternating with etoposide and cisplatin)^{65,66} or EP/EMA (etoposide and cisplatin alternating with etoposide, methotrexate, and dactinomycin)⁶⁷
- MEA (methotrexate, etoposide, dactinomycin)⁶⁸
- MAC (methotrexate, dactinomycin, and chlorambucil)⁶⁹
- FA (5-FU and dactinomycin)⁷⁰
- MEF (methotrexate, etoposide, and 5-FU)⁷¹
- CHAMOCA (methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine)⁶⁹

Due to the lack of RCTs in this setting, systematic reviews have been unable to draw conclusions regarding a superior combination regimen for primary treatment of high-risk GTN.^{46,72} EMA/EP (or EP/EMA) is highly active and considered by some to be superior to EMA/CO for ultra-high-risk disease; however, its use as standard

initial therapy is limited by increased toxicity and inability to provide adequate salvage chemotherapy if required for persistent/recurrent disease.^{4,67}

Induction Chemotherapy for Ultra-High-Risk Disease

Patients with widespread metastatic GTN, as evidenced by a prognostic score >12, have a poorer prognosis.^{73,74} Initiation of standard combination chemotherapy in these patients can lead to tumor collapse with hemorrhage, metabolic acidosis, septicemia, and/or multiple organ failure, resulting in the potential for early death (ie, within 4 weeks).^{18,52,74} Efforts to improve outcomes for this ultra-high-risk population have included induction chemotherapy with etoposide and cisplatin before starting EMA/CO.^{52,74} In a case series of 140 patients with high-risk GTN, 33 patients who were determined to have large disease burden (ie, ultra-high-risk GTN) received low-dose induction chemotherapy with etoposide/cisplatin before EMA/CO therapy (etoposide 100 mg/m² intravenously and cisplatin 20 mg/m² intravenously on days 1 and 2, every 7 days for 1–3 courses). Overall survival and early death rate were 94.3% and 0.7%, respectively, for the high-risk GTN cohort, representing a considerable improvement over outcomes reported for an earlier cohort who did not receive induction chemotherapy.⁵²

PRINCIPLES OF SYSTEMIC THERAPY

High-Risk GTN: Therapy for Methotrexate-Resistant GTN^a

TP/TE: Paclitaxel, Cisplatin / Paclitaxel, Etoposide (Repeat every 2 weeks) • Paclitaxel 135 mg/m ² IV infusion on day 1 • Cisplatin 75 mg/m ² IV on day 1 Alternating every 2 weeks with: • Paclitaxel 135 mg/m ² IV infusion on day 15 • Etoposide 150 mg/m ² IV on day 15 • Administer pegfilgrastim, 6 mg SC on days 2 and 16	TIP: Paclitaxel, Ifosfamide, Cisplatin (Repeat every 3 weeks) • Paclitaxel 250 mg/m ² IV on day 1 • Ifosfamide 1500 mg/m ² IV on days 2–5 • Mesna 300 mg/m ² IV before ifosfamide, then at 4 hours and 8 hours from the start of each ifosfamide dose on days 2–5 • Cisplatin 25 mg/m ² /day IV on days 2–5
BEP: Bleomycin, Etoposide, Cisplatin (Repeat every 3 weeks) • Bleomycin 30 units IV on days 1, 8, and 15 • Etoposide 100 mg/m ² /day IV on days 1–4 • Cisplatin 20 mg/m ² /day IV on days 1–4 • Pegfilgrastim 6 mg SC on day 8; OR Filgrastim 300 mcg SC on days 6–14 Comments/Considerations • Lifetime dose of bleomycin should not exceed 270 units. • Pulmonary function testing should be performed prior to initiation of therapy and every fourth dose thereafter.	ICE: Ifosfamide, Carboplatin, Etoposide (Repeat every 3 weeks) • Ifosfamide 1.2 grams/m ² /day IV on days 1–3 • Mesna 120 mg/m ² /day IV bolus prior to ifosfamide, then 1.2 grams/m ² /day IV infusion over 12 hours after ifosfamide dose on days 1–3 • Carboplatin AUC 4 IV on day 1 • Etoposide 75 mg/m ² /day IV on days 1–3 • Pegfilgrastim 6 mg SC on day 4; OR Filgrastim 300 mcg SC on days 6–14
VIP: Etoposide, Ifosfamide, Cisplatin (Repeat every 3 weeks) • Etoposide 75 mg/m ² /day IV on days 1–4 • Ifosfamide 1.2 grams/m ² /day IV on days 1–4 • Mesna 120 mg/m ² /day IV bolus just prior to ifosfamide, then 1.2 grams/m ² /day IV infusion over 12 hours after ifosfamide dose on days 1–4 • Cisplatin 20 mg/m ² /day IV on days 1–4 • Pegfilgrastim 6 mg SC on day 5; OR Filgrastim 300 mcg SC on days 6–14	Additional agents/regimens shown to have some activity in treating resistant GTN: • PD-1/PD-L1 inhibitors (eg, pembrolizumab, nivolumab) • 5-fluorouracil/capecitabine • Gemcitabine ± carboplatin • High-dose chemotherapy with peripheral stem cell transplant

^aUse G-CSF as primary prophylaxis with etoposide/cisplatin or etoposide/carboplatin-based regimens. See NCCN Guidelines for Myeloid Growth Factors.[†]

Continued

[†]To view the most recent version of these guidelines, visit NCCN.org.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

GTN-A
4 OF 5

Management of Central Nervous System Metastases

Additional treatment considerations are recommended for patients with central nervous system (CNS) metastases, who may require emergency intervention to manage intracranial bleeding or elevated intracranial pressure.^{4,75} Rates of CNS metastases are low with postmolar GTN, but approximately 20% of patients with choriocarcinoma have CNS involvement.⁷⁵ In addition to systemic combination chemotherapy, additional treatment modalities may be used, including whole brain irradiation, stereotactic radiosurgery, and/or craniotomy with surgical excision.^{4,55,76–79} Additionally, EMA/CO should be modified to include high-dose methotrexate dose (1 g/m²) or the addition of intrathecal methotrexate to encourage sufficient blood brain barrier penetration.^{18,78} Reported cure rates with brain metastases range from 50% to 80%, depending on the patient's symptoms and number, size, and location of brain lesions.^{55,75,76,78,80–83}

Adjuvant Surgery

Adjuvant surgical procedures for chemotherapy-resistant disease may be required to manage high-risk disease. Select patients with isolated disease may be candidates for surgical resection, especially for isolated disease in the uterus or lungs.^{84–86} PET/CT imaging may be useful for

detecting isolated metastatic sites that are amenable to targeted surgery.⁸⁷ Additionally, interventional procedures to prevent or control hemorrhage are important components in the management of high-risk GTN.⁴ Selective arterial embolization can be used to manage bleeding from the uterus/vagina or other tumor sites.^{88–90} In one case series, nearly 50% of patients with high-risk disease underwent some form of surgical procedure during the course of treatment to effect cure.⁹¹

Salvage Chemotherapy

Despite the use of multiagent primary therapy, approximately 30% to 40% of patients at high risk will have an incomplete response to first-line therapy or experience relapse from remission.^{92,93} Most of these patients have multiple metastases to sites other than the lung and vagina and many will have received inadequate initial therapy.^{94,95} Salvage chemotherapy with drug regimens employing etoposide and a platinum agent, often combined with surgical resection of persistent tumor, will result in cure of about 80% to 90% of patients with high-risk disease.⁹⁶

The EMA/EP or EP/EMA regimens are considered the most appropriate therapy for patients who have responded to EMA/CO but have plateauing low hCG

PRINCIPLES OF SYSTEMIC THERAPY

Intermediate Trophoblastic Tumor (PSTT and ETT)^a

Regimens	Comments/Considerations
<p>See HIGH-RISK GTN sections for dosage</p> <ul style="list-style-type: none"> • EMA/EP: Etoposide, methotrexate, dactinomycin/etoposide, cisplatin • EP/EMA: Etoposide, cisplatin/etoposide, methotrexate, dactinomycin • TP/TE: Paclitaxel, cisplatin/paclitaxel, etoposide • BEP: Bleomycin, etoposide, cisplatin • VIP: Etoposide, ifosfamide, cisplatin • ICE: Ifosfamide, carboplatin, etoposide 	<p>Additional agents/regimens shown to have some activity in treating resistant GTN:</p> <ul style="list-style-type: none"> • PD-1/PD-L1 inhibitors (eg, pembrolizumab, nivolumab) • 5-fluorouracil/capecitabine • Gemcitabine ± carboplatin • High-dose chemotherapy with peripheral stem cell transplant

^aUse G-CSF as primary prophylaxis with etoposide/cisplatin or etoposide/carboplatin-based regimens. See NCCN Guidelines for Myeloid Growth Factors.[†]

[†]To view the most recent version of these guidelines, visit NCCN.org.

Version 2.2019, 05/06/19 © National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

GTN-A
5 OF 5

levels or have developed re-elevation of hCG after a complete response to EMA/CO.^{97,98} The rate of complete response/remission with EMA/EP for disease resistant to EMA/CO has been reported between 75% and 85%.^{63,97–100}

Additional drug combinations containing etoposide and a platinum agent have been effective in patients who have developed disease resistant to methotrexate-containing regimens. These include TP/TE (paclitaxel and cisplatin alternating weekly with paclitaxel and etoposide), BEP (bleomycin, etoposide, and cisplatin), VIP (etoposide, ifosfamide, and cisplatin), and ICE (ifosfamide, carboplatin, and etoposide).^{46,96,99,101,102} Additionally, TIP (paclitaxel, ifosfamide, and cisplatin) has been used as a salvage chemotherapy regimen in germ cell tumors, including those with choriocarcinoma components.^{103–106}

These etoposide-platinum containing regimens require the use of granulocyte colony-stimulating factor support to prevent neutropenic complications and treatment delays.^{96,101,107} The overall success of salvage therapy in this group of patients is about 80%. Factors associated with worse survival outcomes include high hCG at the start of salvage therapy, greater number of metastatic sites, metastases to sites

other than the lung and vagina (stage IV), and FIGO score >12.

Additional Agents/Regimens With Potential Activity in Treatment-Resistant GTN

Several additional treatment regimens have been shown to have some activity when treating resistant GTN, including high-dose chemotherapy (HDC) with peripheral stem cell transplant, immunotherapy, and other chemotherapy regimens. For a subset of patients with resistant disease despite multidrug chemotherapy, HDC with autologous stem cell support has been reported to produce sustained complete responses.^{108–112} A retrospective study of 32 patients with refractory choriocarcinoma or poor-prognosis PSTT/ETT who underwent HDC with peripheral blood stem cell support reported a sustained complete response in 7 patients, with 13 of 32 patients remaining disease free at the time of analysis after HDC with or without additional therapy.¹¹⁰

Pembrolizumab is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), which functions as a checkpoint protein for regulation of various immune cells, including T cells with potential antitumor activity.^{113–115} Programmed death ligand 1 (PD-L1) is

strongly expressed by GTN.^{116,117} Outcomes were recently reported for 4 patients with drug-resistant GTN who received pembrolizumab, including 2 with metastatic choriocarcinoma and 2 with metastatic PSTT or mixed PSTT/ETT.¹¹⁸ All patients had tumors with high levels of PD-L1 expression. Durable response to pembrolizumab was seen in 3 of the 4 patients. The patient whose disease did not respond to pembrolizumab had strong PD-L1 tumor expression but an absence of tumor-infiltrating lymphocytes.¹¹⁸

Gemcitabine, capecitabine, and fluorouracil may also have potential for treating GTN in this setting. Limited data have suggested activity of gemcitabine, administered with or without a platinum agent.¹¹⁹ Additional support for the potential activity of these regimens in GTN can be found in the data for treating germ cell tumors. Successful use of capecitabine as single-agent salvage chemotherapy has been reported.^{120,121} Groups in Asia have also reported on fluorouracil, primarily in combination with dactinomycin.⁷⁰

Intermediate Trophoblastic Tumors

Whereas molar pregnancies and choriocarcinoma are derived from villous trophoblast (ie, cytotrophoblast and syncytiotrophoblast), ITTs (including PSTT and ETT) develop from extravillous trophoblast (ie, intermediate trophoblast). ITTs comprise approximately 1% of GTN cases, and as such, their biologic behavior and treatment are less well established. These tumors typically develop months to years after normal pregnancies but can occur after any pregnancy event. A recent series of 62 cases of ITT suggested that interval between antecedent pregnancy and disease onset may be longer for ETT than PSTT.¹²²

PSTT and ETT are generally slow-growing tumors that can metastasize months or years after the initial primary has developed and often present with abnormal uterine bleeding or amenorrhea. The vast majority of ITTs secrete hCG but at significantly lower levels compared with other types of GTN. As such, hCG is a less reliable tumor marker for these subtypes of GTN. At diagnosis, metastases are noted in 30% to 50% of cases, most commonly to the lungs. Unlike other GTNs, these have a greater propensity for lymphatic spread. Data are currently being collected in a global database of PSTTs and ETTs through the efforts of the International Society for the Study of Trophoblastic Disease.^{10,123–128}

ITTs can be differentiated from other types of GTN via their histopathologic characteristics.¹⁰ In PSTT, immunohistochemical staining reveals the diffuse presence of cytokeratin, Mel-CAM, and human placental lactogen (hPL), whereas hCG staining is only focal. Cytogenetic

studies have revealed that PSTTs are more often diploid than aneuploid.¹²⁹ Serum hPL measurements are not clinically useful in monitoring disease course or guiding clinical management.^{126,127,130,131} ETT is distinguished from PSTT by its smaller, fairly monomorphic cells and a nested, nodular, well-circumscribed growth pattern. Immunohistochemistry reveals strong expression of p63, but only focal to weak expression of Mel-CAM and hPL.¹³² It frequently involves the lower uterine segment and endocervix, and because of its epithelioid histologic appearance and expression of p63 and cytokeratins, ETT can be confused with squamous cell carcinoma.^{10,132,133}

Due to the rarity of these tumors, generally small cohort sizes preclude rigorous statistical analysis of risk factors in ITT. The FIGO prognostic scoring system for GTN does not correlate well with outcomes in PSTT and ETT.¹⁰ Based on findings from the largest existing database, PSTT and ETT accounted for 125 of 54,743 cases of GTD (0.23%), with posttreatment 5- and 10-year survival estimates of 80% and 75%, respectively. The most important prognostic factors include advanced disease stage and interval from last known pregnancy event of ≥ 48 months.^{124,127,128,134} Additional risk factors associated with less favorable outcomes are advancing age, deep myometrial invasion, tumor necrosis, large tumor size, and mitotic index.^{10,128,135}

Treatment Approach

ITTs are relatively chemoresistant and thus follow a somewhat different treatment paradigm than invasive mole and choriocarcinoma, with surgical intervention playing a more critical role. Treatment of PSTT and ETT is determined mainly based on presence or absence of metastatic disease with some consideration given to high-risk factors. Hysterectomy with lymph node dissection is the recommended treatment of localized disease. Metastasectomy should be used for isolated distant disease, especially in the lungs. Chemotherapy is given to patients with metastatic disease, and it should be considered for patients with nonmetastatic disease who have any of the adverse prognostic factors noted previously.¹³⁶

Although the optimal chemotherapy regimen for PSTT and ETT remains to be defined, the current clinical impression is that a platinum/etoposide-containing regimen, such as EMA/EP or TP/TE, is the treatment of choice. The survival rate is approximately 100% for nonmetastatic disease and 50% to 60% for metastatic disease. Increased use of platinum-based chemotherapy and HDC over time has led to improved overall survival for the subset of patients with ITT who have an overall poor prognosis (ie, interval ≥ 48 months from last known pregnancy event).^{124,126–128}

References

- Altieri A, Franceschi S, Ferlay J, et al. Epidemiology and aetiology of gestational trophoblastic diseases. *Lancet Oncol* 2003;4:670–678.
- Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. *Am J Obstet Gynecol* 2010;203:531–539.
- Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. *Lancet* 2010;376:717–729.
- Brown J, Naumann RW, Seckl MJ, et al. 15 years of progress in gestational trophoblastic disease: scoring, standardization, and salvage. *Gynecol Oncol* 2017;144:200–207.
- Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. *Am J Obstet Gynecol* 2011;204:11–18.
- Berkowitz RS, Goldstein DP. Current advances in the management of gestational trophoblastic disease. *Gynecol Oncol* 2013;128:3–5.
- Berkowitz RS, Goldstein DP. Chorionic tumors. *N Engl J Med* 1996;335:1740–1748.
- Berkowitz RS, Goldstein DP. Clinical practice. Molar pregnancy. *N Engl J Med* 2009;360:1639–1645.
- Sun SY, Melamed A, Goldstein DP, et al. Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia? *Gynecol Oncol* 2015;138:46–49.
- Horowitz NS, Goldstein DP, Berkowitz RS. Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. *Gynecol Oncol* 2017;144:208–214.
- Shaaban AM, Rezvani M, Haroun RR, et al. Gestational trophoblastic disease: clinical and imaging features. *Radiographics* 2017;37:681–700.
- Hancock BW, Tidy JA. Current management of molar pregnancy. *J Reprod Med* 2002;47:347–354.
- Ngan HY, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease. *Int J Gynaecol Obstet* 2015;131(Suppl 2):S123–S126.
- Zhao P, Lu Y, Huang W, et al. Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review and meta-analysis. *BMC Cancer* 2019;19:13.
- Wang Q, Fu J, Hu L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. *Cochrane Database Syst Rev* 2017;9:CD007289.
- Berkowitz RS, Goldstein DP. Gestational trophoblastic disease. *Cancer* 1995; 76(10 Suppl):2079–2085.
- Cole LA. Human chorionic gonadotropin and associated molecules. *Expert Rev Mol Diagn* 2009;9:51–73.
- Ngan HYS, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease. *Int J Gynaecol Obstet* 2018;143(Suppl 2):79–85.
- Muller CY, Cole LA. The quagmire of hCG and hCG testing in gynecologic oncology. *Gynecol Oncol* 2009;112:663–672.
- Coyle C, Short D, Jackson L, et al. What is the optimal duration of human chorionic gonadotropin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients. *Gynecol Oncol* 2018;148:254–257.
- Schmitt C, Doret M, Massardier J, et al. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type. *Gynecol Oncol* 2013;130:86–89.
- Braga A, Maestá I, Matos M, et al. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation. *Gynecol Oncol* 2015;139:283–287.
- FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. *Int J Gynaecol Obstet* 2002;77:285–287.
- Eysbouts YK, Massuger L, Int'Hout J, et al. The added value of hysterectomy in the management of gestational trophoblastic neoplasia. *Gynecol Oncol* 2017;145:536–542.
- Doll KM, Soper JT. The role of surgery in the management of gestational trophoblastic neoplasia. *Obstet Gynecol Surv* 2013;68:533–542.
- Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. *Gynecol Oncol* 2004;95:423–429.
- Garner EI, Feltmate CM, Goldstein DP, et al. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. *Gynecol Oncol* 2005;99:3–5.
- van Trommel NE, Thomas CM, Massuger LF, et al. Second curettage in persistent trophoblastic disease (PTD): the need for univocal definition of PTD. *Gynecol Oncol* 2005;99:250–251, author reply 251.
- Osborne RJ, Filiaci VL, Schink JC, et al. Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. *Obstet Gynecol* 2016;128:535–542.
- Savage P, Seckl MJ. The role of repeat uterine evacuation in trophoblast disease. *Gynecol Oncol* 2005;99:251–252, author reply 252–253.
- May T, Goldstein DP, Berkowitz RS. Current chemotherapeutic management of patients with gestational trophoblastic neoplasia. *Chemother Res Pract* 2011;2011:806256.
- Rotmensh S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. *Lancet* 2000;355:712–715.
- Cole LA, Muller CY. Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. *Gynecol Oncol* 2010;116:3–9.
- Ngan HY, Bender H, Benedet JL, et al. FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. *Int J Gynaecol Obstet* 2003;83(Suppl 1):175–177.
- Gestational trophoblastic diseases. Report of a WHO Scientific Group. *World Health Organ Tech Rep Ser* 1983;692:7–81.
- Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. *Cancer* 1976;38:1373–1385.
- Goldstein DP, Berkowitz RS, Horowitz NS. Optimal management of low-risk gestational trophoblastic neoplasia. *Expert Rev Anticancer Ther* 2015;15:1293–1304.
- Mangili G, Lorusso D, Brown J, et al. Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. *Int J Gynecol Cancer* 2014; 24(9, Suppl 3):S109–S116.
- Lawrie TA, Alazzam M, Tidy J, et al. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. *Cochrane Database Syst Rev* 2016;6:CD007102.
- Schink JC, Filiaci V, Huang H, et al. A phase III randomized trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia [abstract]. Presented at the XIX World Congress of the International Society for the Study of Trophoblastic Diseases; September 21–24, 2017; Amsterdam, The Netherlands.
- Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. *J Clin Oncol* 2011;29:825–831.
- Kohorn EI. Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance? *Gynecol Oncol* 2002;85:36–39.
- Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009. *Br J Cancer* 2012; 107:1810–1814.
- Hitchins RN, Holden L, Newlands ES, et al. Single agent etoposide in gestational trophoblastic tumours: experience at Charing Cross Hospital 1978–1987. *Eur J Cancer Clin Oncol* 1988;24:1041–1046.
- Sung HC, Wu PC, Yang HY. Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms. *Am J Obstet Gynecol* 1984;150:69–75.
- Alazzam M, Tidy J, Osborne R, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. *Cochrane Database Syst Rev* 2016;1:CD008891.
- Covens A, Filiaci VL, Burger RA, et al. Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. *Cancer* 2006;107: 1280–1286.
- McNeish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. *J Clin Oncol* 2002;20:1838–1844.
- McGrath S, Short D, Harvey R, et al. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). *Br J Cancer* 2010; 102:810–814.

50. Lurain JR, Chapman-Davis E, Hoekstra AV, et al. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia. *J Reprod Med* 2012;57:283–287.
51. Prouvot C, Golfier F, Massardier J, et al. Efficacy and safety of second-line 5-day dactinomycin in case of methotrexate failure for gestational trophoblastic neoplasia. *Int J Gynecol Cancer* 2018;28:1038–1044.
52. Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. *J Clin Oncol* 2013;31:280–286.
53. Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. *J Reprod Med* 2006;51:767–772.
54. Ahamed E, Short D, North B, et al. Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving? *J Reprod Med* 2012;57:262–269.
55. Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. *J Reprod Med* 2002;47:465–471.
56. Crawford RA, Newlands E, Rustin GJ, et al. Gestational trophoblastic disease with liver metastases: the Charing Cross experience. *Br J Obstet Gynaecol* 1997;104:105–109.
57. Newlands ES, Bagshawe KD, Begent RH, et al. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. *Br J Obstet Gynaecol* 1991;98:550–557.
58. Bolis G, Bonazzi C, Landoni F, et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). *Gynecol Oncol* 1988;31:439–444.
59. Kim SJ, Bae SN, Kim JH, et al. Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. *Gynecol Oncol* 1998;71:247–253.
60. Matsui H, Suzuka K, Iitsuka Y, et al. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. *Gynecol Oncol* 2000;78:28–31.
61. Escobar PF, Lurain JR, Singh DK, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. *Gynecol Oncol* 2003;91:552–557.
62. Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. *Int J Gynecol Cancer* 2006;16:1432–1438.
63. Lu WG, Ye F, Shen YM, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. *Int J Gynecol Cancer* 2008;18:357–362.
64. Cagayan MS. High-risk metastatic gestational trophoblastic neoplasia: primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. *J Reprod Med* 2012;57:231–236.
65. Cyriac S, Rajendranath R, Sridevi V, et al. Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia. *Int J Gynaecol Obstet* 2011;115:37–39.
66. Ghaemmaghami F, Modares M, Arab M, et al. EMA-EP regimen, as first line multiple agent chemotherapy in high-risk GTT patients (stage II-IV). *Int J Gynecol Cancer* 2004;14:360–365.
67. Han SN, Amant F, Leunen K, et al. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia. *Int J Gynecol Cancer* 2012;22:875–880.
68. Dobson LS, Lorigan PC, Coleman RE, et al. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. *Br J Cancer* 2000;82:1547–1552.
69. Curry SL, Blessing JA, DiSaia PJ, et al. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in “poor prognosis” metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. *Obstet Gynecol* 1989;73:357–362.
70. Zhao Y, Zhang W, Duan W. Management of gestational trophoblastic neoplasia with 5-fluorouracil and actinomycin D in northern China. *J Reprod Med* 2009;54:88–94.
71. Wang S, An R, Han X, et al. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences. *Gynecol Oncol* 2006;103:1105–1108.
72. Deng L, Yan X, Zhang J, et al. Combination chemotherapy for high-risk gestational trophoblastic tumour. *Cochrane Database Syst Rev* 2009; (2): CD005196.
73. Kong Y, Yang J, Jiang F, et al. Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: a retrospective cohort study. *Gynecol Oncol* 2017;146:81–86.
74. Bolze PA, Riedl C, Massardier J, et al. Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥ 13 . *Am J Obstet Gynecol* 2016;214: 390.e391–390.e8.
75. Savage P, Kelpandides I, Tuthill M, et al. Brain metastases in gestational trophoblastic neoplasia: an update on incidence, management and outcome. *Gynecol Oncol* 2015;137:73–76.
76. Gavanier D, Leport H, Massardier J, et al. Gestational trophoblastic neoplasia with brain metastasis at initial presentation: a retrospective study. *Int J Clin Oncol* 2019;24:153–160.
77. Piura E, Piura B. Brain metastases from gestational trophoblastic neoplasia: review of pertinent literature. *Eur J Gynaecol Oncol* 2014;35:359–367.
78. Neubauer NL, Latif N, Kalakota K, et al. Brain metastasis in gestational trophoblastic neoplasia: an update. *J Reprod Med* 2012;57:288–292.
79. Soper JT, Spillman M, Sampson JH, et al. High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. *Gynecol Oncol* 2007;104:691–694.
80. Rustin GJ, Newlands ES, Begent RH, et al. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. *J Clin Oncol* 1989;7:900–903.
81. Evans AC, Jr., Soper JT, Clarke-Pearson DL, et al. Gestational trophoblastic disease metastatic to the central nervous system. *Gynecol Oncol* 1995;59:226–230.
82. Small W, Jr., Lurain JR, Shetty RM, et al. Gestational trophoblastic disease metastatic to the brain. *Radiology* 1996;200:277–280.
83. Bakri Y, Berkowitz RS, Goldstein DP, et al. Brain metastases of gestational trophoblastic tumor. *J Reprod Med* 1994;39:179–184.
84. Alazzam M, Hancock BW, Tidy J. Role of hysterectomy in managing persistent gestational trophoblastic disease. *J Reprod Med* 2008;53:519–524.
85. Fleming EL, Garrett L, Growdon WB, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. *J Reprod Med* 2008;53:493–498.
86. Kanis MJ, Lurain JR. Pulmonary resection in the management of high-risk gestational trophoblastic neoplasia. *Int J Gynecol Cancer* 2016;26:796–800.
87. Mapelli P, Mangili G, Picchio M, et al. Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. *Eur J Nucl Med Mol Imaging* 2013;40:505–513.
88. Lim AK, Agarwal R, Seckl MJ, et al. Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. *Radiology* 2002;222:640–644.
89. Tse KY, Chan KK, Tam KF, et al. 20-year experience of managing profuse bleeding in gestational trophoblastic disease. *J Reprod Med* 2007;52:397–401.
90. McGrath S, Harding V, Lim AK, et al. Embolization of uterine arteriovenous malformations in patients with gestational trophoblastic tumors: a review of patients at Charing Cross Hospital, 2000–2009. *J Reprod Med* 2012;57:319–324.
91. Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. *J Reprod Med* 2006;51:773–776.
92. Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. *Br J Cancer* 2007;96:732–737.
93. Hoekstra AV, Lurain JR, Rademaker AW, et al. Gestational trophoblastic neoplasia: treatment outcomes. *Obstet Gynecol* 2008;112:251–258.
94. Lurain JR, Casanova LA, Miller DS, et al. Prognostic factors in gestational trophoblastic tumors: a proposed new scoring system based on multivariate analysis. *Am J Obstet Gynecol* 1991;164:611–616.
95. Lurain JR, Hoekstra AV, Schink JC. Results of treatment of patients with gestational trophoblastic neoplasia referred to the Brewer Trophoblastic

- Disease Center after failure of treatment elsewhere (1979-2006). *J Reprod Med* 2008;53:535-540.
96. Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. *J Reprod Med* 2012;57:219-224.
 97. Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. *J Clin Oncol* 2000;18:854-859.
 98. Mao Y, Wan X, Lv W, et al. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. *Int J Gynaecol Obstet* 2007;98:44-47.
 99. Anantharaju AA, Pallavi VR, Bafna UD, et al. Role of salvage therapy in chemo resistant or recurrent high-risk gestational trophoblastic neoplasia. *Int J Gynecol Cancer* 2019;29:547-553.
 100. Lurain JR, Singh DK, Schink JC. Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7. *J Reprod Med* 2010;55:199-207.
 101. Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). *Ann Oncol* 2008;19:1578-1583.
 102. Essel KG, Bruegl A, Gershenson DM, et al. Salvage chemotherapy for gestational trophoblastic neoplasia: utility or futility? *Gynecol Oncol* 2017;146:74-80.
 103. Feldman DR, Hu J, Dorff TB, et al. Paclitaxel, ifosfamide, and cisplatin efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors. *J Clin Oncol* 2016;34:2478-2483.
 104. Mardiak J, Rejlekova K, Mego M, et al. Determination of efficacy of TIP combination (paclitaxel, ifosfamide, cisplatin) as first salvage therapy for patients with relapsed germ cell tumors in a poor prognosis group [published online December 12, 2016]. *J Clin Oncol* doi: 10.1200/jco.2009.27.15_suppl.e16049
 105. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. *J Clin Oncol* 2005;23:6549-6555.
 106. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. *J Clin Oncol* 2000;18:2413-2418.
 107. Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. *Gynecol Oncol* 2005;97:618-623.
 108. Benigno BB. High-dose chemotherapy with autologous stem cell support as salvage therapy in recurrent gestational trophoblastic disease. *Int J Gynecol Cancer* 2013;23:1331-1333.
 109. El-Helw LM, Seckl MJ, Haynes R, et al. High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. *Br J Cancer* 2005;93:620-621.
 110. Frijstein MM, Lok CAR, Short D, et al. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. *Eur J Cancer* 2019;109:162-171.
 111. van Besien K, Verschraegen C, Mehra R, et al. Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. *Gynecol Oncol* 1997;65:366-369.
 112. Yamamoto E, Niimi K, Fujikake K, et al. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: a case report and literature review. *Mol Clin Oncol* 2016;5:660-664.
 113. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. *Am J Clin Oncol* 2016;39:98-106.
 114. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. *Clin Cancer Res* 2012;18:6580-6587.
 115. Wherry EJ. T cell exhaustion. *Nat Immunol* 2011;12:492-499.
 116. Bolze PA, Patrier S, Massardier J, et al. PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes. *Int J Gynecol Cancer* 2017;27:554-561.
 117. Veras E, Kurman RJ, Wang TL, et al. PD-L1 expression in human placenta and gestational trophoblastic diseases. *Int J Gynecol Pathol* 2017;36:146-153.
 118. Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. *Lancet* 2017;390:2343-2345.
 119. Pandian Z, Seckl MJ, Smith R, et al. Gestational choriocarcinoma: an unusual presentation with response to gemcitabine and surgery. *BJOG* 2004;111:382-384.
 120. Bianconi MI, Otero S, Storino C, et al. Role of capecitabine in the management of gestational trophoblastic neoplasia: a drug for two settings. *J Reprod Med* 2017;62:250-256.
 121. Bianconi M, Jankilevich G, Otero S, et al. Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine. *Gynecol Oncol* 2007;106:268-271.
 122. Zhang Y, Zhang S, Huang W, et al. Intermediate trophoblastic tumor: the clinical analysis of 62 cases and prognostic factors. *Arch Gynecol Obstet* 2019;299:1353-1364.
 123. Lan C, Li Y, He J, et al. Placental site trophoblastic tumor: lymphatic spread and possible target markers. *Gynecol Oncol* 2010;116:430-437.
 124. Frijstein MM, Lok CAR, van Trommel NE, et al. all the contributors to the ISSTD PSTT/ETT database. Management and prognostic factors of epithelioid trophoblastic tumors: results from the International Society for the Study of Trophoblastic Diseases database. *Gynecol Oncol* 2019;152:361-367.
 125. Kurman RJ, Shih IM. Discovery of a cell: reflections on the checkered history of intermediate trophoblast and update on its nature and pathologic manifestations. *Int J Gynecol Pathol* 2014;33:339-347.
 126. Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. *Lancet* 2009;374:48-55.
 127. Zhao J, Lv WG, Feng FZ, et al. Placental site trophoblastic tumor: a review of 108 cases and their implications for prognosis and treatment. *Gynecol Oncol* 2016;142:102-108.
 128. Froeling FEM, Ramaswami R, Papanastasopoulos P, et al. Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. *Br J Cancer* 2019;120:587-594.
 129. Baergen RN, Rutgers JL, Young RH, et al. Placental site trophoblastic tumor: a study of 55 cases and review of the literature emphasizing factors of prognostic significance. *Gynecol Oncol* 2006;100:511-520.
 130. Papadopoulos AJ, Foskett M, Seckl MJ, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. *J Reprod Med* 2002;47:460-464.
 131. Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumour: clinical features and management. *Gynecol Oncol* 2005;99:603-607.
 132. Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. *Am J Surg Pathol* 1998;22:1393-1403.
 133. Allison KH, Love JE, Garcia RL. Epithelioid trophoblastic tumor: review of a rare neoplasm of the chorionic-type intermediate trophoblast. *Arch Pathol Lab Med* 2006;130:1875-1877.
 134. Yang J, Zong L, Wang J, et al. Epithelioid trophoblastic tumors: treatments, outcomes, and potential therapeutic targets. *J Cancer* 2019;10:11-19.
 135. Hancock B, Froeling FEM, Ramaswami R, et al. The ISSTD global placental site and epithelioid trophoblastic tumor (PSTT/ETT) database – an analysis of 326 patients. Presented at the ISSTD XVIII World Congress on Gestational Trophoblastic Disease; 2015; Bali, Indonesia.
 136. Sobocki-Rausch J, Winder A, Maniar KP, et al. Surgery and platinum/etoposide-based chemotherapy for the treatment of epithelioid trophoblastic tumor. *Int J Gynecol Cancer* 2018;28:1117-1122.

Individual Disclosures for the NCCN Gestational Trophoblastic Neoplasia Panel

Panel Member	Clinical Research Support/ Data Safety Monitoring Board	Scientific Advisory Boards, Consultant, or Expert Witness	Promotional Advisory Boards, Consultant, or Speakers Bureau	Specialties
Nadeem R. Abu-Rustum, MD	GRAIL, Inc.; Olympus/prIME Oncology, Inc.; Stryker/Novadaq; and UpToDate, Inc.	None	None	Gynecologic Oncology
Sarah Bean, MD	None	None	None	Pathology
Kristin Bradley, MD	None	None	None	Radiotherapy/Radiation Oncology
Susana M. Campos MD, MPH, MS ^a	None	Clovis Oncology	None	Medical Oncology
Hye Sook Chon, MD	None	None	None	Gynecologic Oncology
Christina Chu, MD	None	None	None	Gynecologic Oncology
David Cohn, MD	AbbVie, Inc.; Advaxis, Inc.; Agenus Inc.; Ajinomoto Co., Inc.; Array BioPharma Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Clovis Oncology; Eisai Inc.; EMD Serono, Inc.; ERGOMED Clinical Research; Exelixis Inc.; GlaxoSmithKline; GOG Partners; Henry Jackson Foundation; ImmunoGen, Inc.; INC Research; inVentiv Health Clinical; Janssen Pharmaceutica Products, LP; Ludwig Institute for Cancer Research; Novartis Pharmaceuticals Corporation; NRG Oncology; Pfizer Inc.; PharMar; PRA International; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; Stemcentrx, Inc.; TESARO, Inc.; and TRACON Pharmaceuticals, Inc.	Oncology Analytics, and UpToDate, Inc.	None	Gynecologic Oncology
Marta Ann Crispens, MD	Advaxis, Inc.; AstraZeneca Pharmaceuticals LP; BeiGene; Incyte Corporation; Innovio Pharmaceuticals; Leap Therapeutics, Inc.; Puma Biotechnology; Roche Laboratories, Inc.; Taiho Pharmaceuticals Co., Ltd.; and TESARO, Inc.	AstraZeneca Pharmaceuticals LP	None	Gynecologic Oncology
Shari Damast, MD	None	None	None	Radiotherapy/Radiation Oncology
Oliver Dorigo, MD, PhD	ImmunoVaccine Technologies Inc.	Merck & Co., Inc., and TESARO, Inc.	AstraZeneca Pharmaceuticals LP, and TESARO, Inc.	Gynecologic Oncology
Patricia J. Eifel, MD	None	None	None	Radiotherapy/Radiation Oncology
Christine M. Fisher MD, MPH	None	Accuray Incorporated	None	Radiotherapy/Radiation Oncology
Peter Frederick, MD	None	None	None	Gynecologic Oncology
David K. Gaffney MD, PhD	Elekta	None	None	Radiotherapy/Radiation Oncology
Ernest Han, MD, PhD	None	None	None	Gynecologic Oncology
Warner K. Huh, MD	Inovio Pharmaceuticals	Antiva Biosciences	None	Gynecologic Oncology
John R. Lurain, III, MD	None	None	None	Gynecologic Oncology
Andrea Mariani, MD	None	None	None	Gynecologic Oncology
David Mutch, MD	None	None	AstraZeneca Pharmaceuticals LP, and Clovis Oncology	Gynecologic Oncology
Christa Nagel, MD	None	None	None	Gynecologic Oncology
Larissa Nekhlyudov, MD, MPH	None	None	None	Internal Medicine
Amanda Nickles Fader, MD	None	Merck & Co., Inc.	Ethicon, Inc.	Gynecologic Oncology
Steven W. Remmenga, MD	None	NCCN Radius	Humana-TRICARE Quality Committee	Gynecologic Oncology
R. Kevin Reynolds, MD	None	None	None	Gynecologic Oncology
Rachel Sisodia, MD	None	None	None	Gynecologic Oncology
Todd Tillmanns, MD	AstraZeneca Pharmaceuticals LP	Clovis Oncology	None	Gynecologic Oncology
Stefanie Ueda, MD	None	None	None	Gynecologic Oncology
Emily Wyse	None	None	None	Patient Advocacy
Catheryn M. Yashar, MD	None	None	None	Radiotherapy/Radiation Oncology

The NCCN Guidelines Staff have no conflicts to disclose.

^aThe following individuals have disclosed that they have an employment/governing board, patent, equity, or royalty:

Susana M. Campos, MD, MPH, MS: Eisai Inc.